期刊文献+

直肠癌化疗患者医院感染危险因素分析 被引量:1

Risk factors for nosocomial infections in rectal carcinoma patients undergoing chemotherapy
原文传递
导出
摘要 目的观察直肠癌化疗患者医院感染发生的危险因素,分析其在不同临床特征中感染率的差异,以期为临床工作提供理论帮助。方法对医院630例直肠癌化疗患者的危险因素和临床特征进行分析研究。结果共121例患者发生医院感染,医院感染率为19.21%,其中呼吸道83例占68.60%,泌尿系7例占5.79%,胃肠道5例占4.12%,造瘘口21例占17.36%,皮肤3例占2.48%,血液2例占1.65%;医院感染的发生与性别、年龄、住院时间、手术、白细胞计数、侵入性操作、抗菌药物的使用密切相关(P<0.05)。结论直肠癌化疗患者应重点监测,加强重点患者的风险监测,同时进行有效的干预措施,对减少直肠癌化疗医院感染的发生有重要价值。 OBJECTIVE To observe the risk factors of nosocomial infections in the rectal carcinoma patients undergoing chemotherapy and analyze the infections rate of the patients with different clinical features so as to guide theclinical treatment. METHODS The risk factors for the nosocomial infections in 630 rectal cancer patients undergo-ing chemotherapy were analyzed, and the clinical features were observed. RESULTS The nosocomial infections oc-curred in 121 cases of patients with the incidence rate of 19. 21 %,including 83 (68. 60%) cases with respiratorytract infections,7(5. 79%) cases with urinary tract infections,5 (4. 12%) cases with gastrointestinal tract infections ,21(17. 36%) cases with fistula infections, 3 (2. 48%) cases with skin infections, and 2 (1. 65%) caseswith blood infections. The incidence of the nosocomial infections was closely related to the gender, age,hospitalization duration,surgery, leukocyte count, invasive operation,or use of antibiotics (P〈0. 05). CONCLUSION It isnecessary to focus on the monitoring of the patients undergoing chemotherapy, strengthen the risk surveillance,and take effective interventions so as to reduce the incidence of nosocomial infections in the rectal carcinoma pa-tients undergoing chemotherapy.
出处 《中华医院感染学杂志》 CAS CSCD 北大核心 2013年第17期4146-4147,共2页 Chinese Journal of Nosocomiology
关键词 直肠癌 化疗 医院感染 危险因素 Rectal carcinoma Chemotherapy Nosocomial infection Risk factor
  • 相关文献

参考文献2

二级参考文献57

  • 1张思维,雷正龙,李光琳,邹小农,陈万青,赵平.中国肿瘤登记地区2005年发病死亡资料分析[J].中国肿瘤,2009,18(12):973-979. 被引量:33
  • 2徐志巧,李宁,帖晓静,高岭,刘建民,刘培杰.奥沙利铂和希罗达或醛氢叶酸等治疗结直肠癌研究[J].医药论坛杂志,2007,28(8):59-60. 被引量:6
  • 3Goldberg RM,Meropol NJ,Tabemero J, et al. Accomplishments in 2008 in the treatment of advanced metastatic colorectal cancer [J]. Castrointest Cancer Res, 2009, 3(Suppl 2):S23-S27.
  • 4Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statistics, 2001 [J]. CA Cancer J Clin, 2001,51(1):15-36.
  • 5Andra T, Boni C, Mounedji-Boudiaf L, et al. Multieenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J]. N Engl J Med, 2004, 350(23):2343-2351.
  • 6Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma [J]. N Engl J Med, 1990, 322 (6): 352-358.
  • 7Falcone A, Masi G, Brunetti I, et al. The triplet combination of irinoteean, oxaliplatin and 5FU/LV (FOLFOXIRI) vs the doublet of irinotecan and 5FU/LV (FOI,FIRI) as first-line treatment of metastatic colorectal cancer (MCRC): resuits of a randomized phase III trial by the Gruppo Oncologico Nord Ovest(G.O. N.O.)[J]. J Clin Oncol, 2006, 24:18S.
  • 8Andra T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial [J]. J Clin Oncol, 2009, 27(19): 3109-3116.
  • 9de Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study [J]. J Clin Oncol, 1997, 15(2):808-815.
  • 10Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Metaanalysis Group In Cancer [J]. J Clin Oncol, 1998, 16(1): 301-308.

共引文献26

同被引文献7

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部